kigamicin D: discovered from the culture broth of Amycolatopsis sp. ML630-mF1 by the killing activity against PANC-1 cells only under a nutrient starved condition; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10056728 |
| MeSH ID | M0465032 |
| Synonym |
|---|
| kigamicin d |
| 2,6,9,30-tetrahydroxy-8-[5-[5-(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-4-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-23-methyl-11,14,16,24-tetraoxa-27-azaoctacyclo[15.14.1.03,12.05,10.013,32.019,31.021,29.023,27]dotriaconta-1(32),2,5(10),12,19,2 |
Kigamicin D is a novel anticancer agent. It was identified using a new screening strategy that targets the tolerance of cancer cells to nutrient starvation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Kigamicin D is a novel anticancer agent that was identified using a new screening strategy that targets the tolerance of cancer cells to nutrient starvation [1, 2]. " | ( Antitumor effect of kigamicin D on mouse tumor models. Esumi, H; Ikeda, D; Kawada, M; Kunimoto, S; Masuda, T; Ohba, S; Osono, M, 2006) | 2.1 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " When tested against syngeneic tumors, kigamicin D showed a weak antitumor effect against colon26, but showed augmentation of tumor growth on IMC carcinoma at a broad dosage level." | ( Antitumor effect of kigamicin D on mouse tumor models. Esumi, H; Ikeda, D; Kawada, M; Kunimoto, S; Masuda, T; Ohba, S; Osono, M, 2006) | 0.93 |
| " Instead, delayed-type hypersensitivity response to sheep red blood cells was stimulated at a broad dosage level." | ( Augmentation of cellular immunity by kigamicin D. Iijima, M; Ikeda, D; Inoue, H; Kawada, M; Kunimoto, S; Masuda, T; Ohba, S; Osono, M, 2006) | 0.61 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||